NICE Bites May 2018: No 107: Sore throat (acute); antimicrobial prescribing NICE NG84: 2018: Otitis Media (acute); antimicrobial prescribing NICE NG91; 2018 – NICE

Prescribing bulletin published by North West Medicines Information centre which summarises key recommendations from NICE guidance. NICE Bites No 107 May 2018 includes two topics, covering assessment, treatment and management, general advice, self-care advice, ‘no prescription’ advice, ‘back-up’ prescription advice,

The Sepsis Manual: 4th edition 2017 -2018 – The Sepsis Trust

Looks at the epidemiology of sepsis finding that while the recording of the number of cases of sepsis has improved and there is a better understanding of its impact on the NHS and society, we still have to estimate figures

Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma: Technology appraisal guidance [TA524] – NICE

Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults. This guidance is a Cancer Drugs Fund reconsideration of brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA446). This guidance replaces TA446.  

Arsenic trioxide for treating acute promyelocytic leukaemia: Technology appraisal guidance [TA526] – NICE

Evidence-based recommendations on arsenic trioxide (Trisenox) for treating acute promyelocytic leukaemia in adults.  

Midostaurin for untreated acute myeloid leukaemia: Technology appraisal guidance [TA523] – NICE

Evidence-based recommendations on midostaurin (Rydapt) for untreated FLT3-mutation-positive acute myeloid leukaemia in adults.

External review of a sample of Local Supervising Authority (England) Supervisory Investigations into the standard of midwifery practice in Maternity Serious Incidents that were conducted between 1 April and 31 December 2016 – NHS England

An independent review report commissioned by NHS England in response to two previous commissions relating to the quality of midwifery supervision. Although statutory supervision has been removed and replaced with a new model of supervision, A-EQUIP, this review document provides

Patient access to ibrutinib for previously treated chronic lymphocytic leukaemia in England – NHS England

This clinical statement gives details about patient access to ibrutinib for chronic lymphocytic leukaemia. It states NHS is funding the cancer drug in line with NICE recommendations.

NICEimpact: cardiovascular disease prevention – NICE

NICE impact reports review how NICE recommendations for evidence-based and cost-effective care are being used in priority areas of the health and care system, helping to improve outcomes where this is needed most.This review focus’ on the impact of Cardiovascular Disease

Local General Practitioners Retention Fund: Guidance for NHS England regional and local office teams – NHS England

This guidance document sets out the availability of new funding in 2018/19 to further support delivery of the commitment set out in the General Practice Forward View (GPFV) to ensure an additional 5,000 extra doctors working in general practice by 2020.

National Dose Banding Table – Capecitabine – NHS England

The national dose banding tables are to be used by hospital trust pharmacy teams to ensure a standard approach to dose banding of chemotherapy across all hospital trusts.

Strimvelis for treating adenosine deaminase deficiency–severe combined immunodeficiency: Highly specialised technologies guidance [HST7] -NICE

Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency.

Atrial fibrillation: Quality standard [QS93] – NICE

This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement. In February 2018, the source guidance and

Refreshing NHS plans for 2018/19 – NHS England and NHS Improvement

Guidance, published jointly by NHS England and NHS Improvement, sets out the plans for the NHS in light of the November 2017 budget announcements. It outlines how the additional funding will impact on emergency and urgent care, elective surgery and

Joint Working Protocol: When a hospital, services or facility closes at short notice – NHS England

Guidance to organisations when a hospital, service or facility closes unavoidably at short notice.  The memorandum gives clear guidance and direction to any organisation involved in a short notice closure to take appropriate and timely action in supporting patients and making

Sore throat (acute): antimicrobial prescribing: NICE guideline [NG84] – NICE

This guideline sets out an antimicrobial prescribing strategy for acute sore throat. It aims to limit antibiotic use and reduce antimicrobial resistance. Acute sore throat is often caused by a virus, lasts for about a week, and most people get

Practical Guidance to SPOT for Improving Sexual and Reproductive Health 2017: Guidelines for Local Authorities – Public Helath England

This guidance is a step by step guide on how to use Spend and Outcome Tool (SPOT) for Local Authorities (LAs) to compare spend data on sexual and reproductive health with sexual and reproductive health outcomes.  Looks at: the potential

Lenvatinib with everolimus for previously treated advanced renal cell carcinoma: Technology appraisal guidance [TA498] – NICE

Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma in adults.

Glecaprevir–pibrentasvir for treating chronic hepatitis C: Technology appraisal guidance [TA499] – NICE

Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults.

Ceritinib for untreated ALK-positive non-small-cell lung cancer: Technology appraisal guidance [TA500] – NICE

Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults.